All treatments
TabletWeight LossLimited

Ozempic® tablet

Daily oral semaglutide for patients who recognize the Ozempic® brand and want a non-injection option in their weight-loss program. Run a daily-pill Ozempic®-aware program with intake, billing, and refill infrastructure built in.

Launch this programSee the stack
Ozempic oral semaglutide tablet
Dose
Once daily
Avg. loss · 26 wks
−4% to −6%
Format
Once-daily oral tablet
Before food
Empty stomach, 30 min before food or oral meds
Rx required
Yes, licensed provider review
Use case
Weight management for non-injection patients
About the medication

A daily oral option for weight-loss patients who recognize the brand

This is the oral semaglutide pathway aligned with the Ozempic® brand for patients who want a non-injection format in their weight-loss program. Doses range from 3 mg to 14 mg once daily and must be taken on an empty stomach with up to 4 ounces of water, then a 30-minute wait before eating or taking other oral meds.

  • Same molecule as injectable Ozempic® in a daily pill form
  • Lower weight-loss ceiling than the higher 50 mg Wegovy® weight-loss tablet
  • Strict empty-stomach dosing window matters for absorption and weight outcomes
  • Good fit for weight-loss patients who reject injections but recognize the brand
Mechanism
GLP-1 receptor agonist, oral SNAC-enabled absorption
Delivery
Once-daily tablet swallowed whole in the morning
Administration
Empty stomach, max 4 oz water, wait 30 min before food or oral meds
Oversight
Every order routed through a licensed provider review
Expected results

Modest weight loss at the brand's daily-pill dosing

Based on PIONEER trial data for oral semaglutide at 7 mg and 14 mg. Weight outcomes at this dose range are meaningful but lower than the 50 mg weight-loss dosing used in OASIS 1 for the Wegovy® tablet.

~5–6%
Avg. weight loss at 14 mg
in PIONEER trial at 52 weeks
~45%
Patients losing ≥5%
at the 14 mg dose
~14%
Patients losing ≥10%
at the 14 mg dose
Mean change in body weight
% change from baseline · weeks 0–68
Ozempic® tablet 14 mgPlacebo
At week 68
−6.0%
Ozempic® tablet 14 mg
At week 68
−1.8%
Placebo
Net difference
−4.2 pts
vs. placebo

Illustrative, based on PIONEER trial outcomes for oral semaglutide 14 mg. Higher weight outcomes are achievable with the 50 mg weight-loss formulation (see Wegovy® tablet). The Ozempic® brand is FDA-labeled for type 2 diabetes; use for chronic weight management is off-label and at provider discretion.

Dosing protocol

Standard titration schedule

Oral semaglutide aligned with the Ozempic® brand starts at 3 mg daily for 30 days, then increases to 7 mg, with an option to step up to 14 mg for additional weight effect.

  1. 1
    Weeks 1–4
    3 mg
    Initiation only, GI tolerance
  2. 2
    Weeks 5–8
    7 mg
    First maintenance dose
  3. 3
    Week 9+
    14 mg
    Higher dose for added weight effect
The Turbopills stack for this program

Everything you need to run an Ozempic®-aware oral weight-loss program

Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.

Product website & ad landing pages
Turbopills AI Studio — ad images & videos
Beta
Dynamic intake forms
Billing & subscriptions
Provider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Patient communications
Experiments & A/B tests
Beta
Ready to launch

Launch an Ozempic®-aware oral weight-loss program in weeks, not quarters.

The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.

Talk to our teamBrowse treatments

Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.

Trademark notice. Ozempic® is a registered trademark of Novo Nordisk A/S. Turbopills is not affiliated with, endorsed by, or sponsored by Novo Nordisk. References to the brand are for educational and operator-scoping purposes only.

Related

Other weight-loss treatments